Cargando…

Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics

BACKGROUND: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes, Guilherme S, Bielinski, Suzette J, Moyer, Ann M, Black III, John Logan, Jacobson, Debra J, Jiang, Ruoxiang, Larson, Nicholas B, St Sauver, Jennifer L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081062/
https://www.ncbi.nlm.nih.gov/pubmed/32214840
http://dx.doi.org/10.2147/PGPM.S239222
_version_ 1783508107637293056
author Lopes, Guilherme S
Bielinski, Suzette J
Moyer, Ann M
Black III, John Logan
Jacobson, Debra J
Jiang, Ruoxiang
Larson, Nicholas B
St Sauver, Jennifer L
author_facet Lopes, Guilherme S
Bielinski, Suzette J
Moyer, Ann M
Black III, John Logan
Jacobson, Debra J
Jiang, Ruoxiang
Larson, Nicholas B
St Sauver, Jennifer L
author_sort Lopes, Guilherme S
collection PubMed
description BACKGROUND: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women. METHODS: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity. RESULTS: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men. DISCUSSION: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications.
format Online
Article
Text
id pubmed-7081062
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70810622020-03-25 Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics Lopes, Guilherme S Bielinski, Suzette J Moyer, Ann M Black III, John Logan Jacobson, Debra J Jiang, Ruoxiang Larson, Nicholas B St Sauver, Jennifer L Pharmgenomics Pers Med Original Research BACKGROUND: Several small studies have previously investigated associations between the cytochrome P450 2D6 (CYP2D6) metabolism and response to opioids. We used a large sample of patients to study associations between CYP2D6 phenotypes and estimated CYP2D6 enzymatic activity scores with pain control and adverse reactions related to codeine and tramadol use. We conducted additional analyses to determine whether our results were consistent among men and women. METHODS: We used data from 2,877 participants in the RIGHT Protocol who were prescribed codeine and/or tramadol between 01/01/2005 and 12/31/2017 and who were not prescribed CYP2D6 inhibitors within 1 year prior to the opioid prescription. CYP2D6 phenotype categories were condensed into four groups: (1) Ultra-rapid and Rapid (n = 61), (2) Normal and Intermediate to Normal (n = 1,448), (3) Intermediate and Intermediate to Poor (n = 1,175), and (4) Poor metabolizer status (n = 193). Opioid-related outcomes included indications of poor pain control or adverse reactions related to medication use. We modeled the risk of each outcome using logistic regression, adjusting for age, sex, race, and ethnicity. RESULTS: The results revealed a trend from poor to ultra-rapid and rapid CYP2D6 phenotypes in which the risk of adverse reactions incrementally increased and the risk of poor pain control incrementally decreased. This trend reached statistical significance among female (but not male) participants. Among normal and intermediate to normal metabolizers, a larger proportion of women experienced adverse reactions relative to men. DISCUSSION: We replicated and extended the findings of previous research indicating associations between CYP2D6 phenotypes and response to opioids. In addition, the observed associations were stronger in women than in men. We recommend sex differences to be factored in future research investigating associations between pharmacogenomics and response to medications. Dove 2020-03-13 /pmc/articles/PMC7081062/ /pubmed/32214840 http://dx.doi.org/10.2147/PGPM.S239222 Text en © 2020 Lopes et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lopes, Guilherme S
Bielinski, Suzette J
Moyer, Ann M
Black III, John Logan
Jacobson, Debra J
Jiang, Ruoxiang
Larson, Nicholas B
St Sauver, Jennifer L
Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
title Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
title_full Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
title_fullStr Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
title_full_unstemmed Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
title_short Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
title_sort sex differences in associations between cyp2d6 phenotypes and response to opioid analgesics
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081062/
https://www.ncbi.nlm.nih.gov/pubmed/32214840
http://dx.doi.org/10.2147/PGPM.S239222
work_keys_str_mv AT lopesguilhermes sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT bielinskisuzettej sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT moyerannm sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT blackiiijohnlogan sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT jacobsondebraj sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT jiangruoxiang sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT larsonnicholasb sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics
AT stsauverjenniferl sexdifferencesinassociationsbetweencyp2d6phenotypesandresponsetoopioidanalgesics